Day 11 - September 24, 2021

Adam Rosendorff testified about laboratory problems before and after Theranos's commercial launch. He said validation of planned general-chemistry tests remained incomplete nine days before launch and that he warned Elizabeth Holmes and Daniel Young about assay readiness, training, and staffing. According to Rosendorff, Holmes appeared nervous and upset when he identified unreliable potassium, sodium, and glucose tests, but the requested launch delay did not occur. Rosendorff described variation among Edison devices, manual exclusion of data points, and the use of modified or conventional third-party analyzers. He testified that he moved HCG testing to a Siemens instrument because he considered the Edison assay unfit for patient care. He also reviewed a patient matter involving a reported HCG result below range, a later result above 2,000, and a provider's report that medication had been discontinued after the negative result; he said he could not identify a clinical explanation for the discrepancy. Rosendorff said he felt pressured to defend or rationalize questionable results when speaking with physicians. He testified that he forwarded concerning emails to a personal account because he doubted Theranos would preserve them during a possible investigation, was considering a qui tam action, and believed disclosure served the public interest. He described an emotional conflict between his obligations within Theranos and his duties as a physician and laboratory director. Outside the jury's presence, the parties addressed possible cross-examination about matters arising after Rosendorff left Theranos. The defense said the material might bear on bias but agreed not to raise it that day. The court deferred a final ruling, invited written submissions, and directed the parties to confer. Testimony was scheduled to resume Tuesday after the weekend recess.